novo nordisk glp 1 GLP-1s for Alzheimer's: announces trial conclusion Details of failed studies cast

doi: 10.1111/j.1365-2826.2008.01745.x, PMID: [DOI] [PMC free article] [PubMed] [Google Scholar] 106

Sanofi has a GLP-1 agonist (combination with basal insulin), but this is not it..

Figure 4 summarises the 3-year adverse events

Dipeptidyl peptidase-4 inhibition prevents nonalcoholic steatohepatitis-associated liver fibrosis and tumor development in mice independently of its anti-diabetic effects

Most patients can minimize these side effects by starting with a low dose and gradually titrating upward

However, it is proposed that ethanol metabolism directly impairs the hepatic redox state by increasing the NADH/NAD + ratio